Citations (85)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Michael M. Lipp, Anthony J. Hickey, Robert Langer & Peter A. LeWitt. (2021) A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson’s disease. Expert Opinion on Drug Delivery 18:11, pages 1559-1569.
Read now
Read now
Robert A. Hauser, Peter A. LeWitt & Cynthia L. Comella. (2021) On demand therapy for Parkinson’s disease patients: Opportunities and choices. Postgraduate Medicine 133:7, pages 721-727.
Read now
Read now
Fabrizio Stocchi, Laura Vacca, Andrea Grassi & Margherita Torti. (2021) An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson’s disease. Expert Opinion on Pharmacotherapy 22:8, pages 965-972.
Read now
Read now
Fabrizio Stocchi, Laura Vacca, Paola Stirpe & Margherita Torti. (2018) Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 14:12, pages 1189-1195.
Read now
Read now
Nicola Tambasco, Simone Simoni, Pasquale Nigro, Federico Paolini Paoletti, Erica Marsili & Paolo Calabresi. (2016) Morning akinesia in Parkinson's disease: challenges and solutions. Journal of Parkinsonism and Restless Legs Syndrome 6, pages 57-63.
Read now
Read now
David Salat-Foix & Oksana Suchowersky. (2012) The management of gastrointestinal symptoms in Parkinson’s disease. Expert Review of Neurotherapeutics 12:2, pages 239-248.
Read now
Read now
Articles from other publishers (79)
S. Demartis, G. Rassu, V. Mazzarello, E. Larrañeta, A. Hutton, R.F. Donnelly, A. Dalpiaz, M. Roldo, A.J. Guillot, A. Melero, P. Giunchedi & E. Gavini. (2023) Delivering hydrosoluble compounds through the skin: what are the chances?. International Journal of Pharmaceutics 646, pages 123457.
Crossref
Crossref
Yehuda Arav & Assaf Zohar. (2023) Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease. Scientific Reports 13:1.
Crossref
Crossref
Rajesh Pahwa, Fernando L. Pagan, Daniel E. Kremens & Marie Saint-Hilaire. (2023) Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods. Neurology and Therapy 12:4, pages 1033-1049.
Crossref
Crossref
Jacob E Earp, Cristina Colon-Semenza & Dara L LoBuono. (2023) Considerations for developing a targeted amino acid supplement for people with Parkinson’s disease that promotes health while accounting for pathophysiology and medication interference. Nutrition Reviews 81:8, pages 1063-1076.
Crossref
Crossref
Zhe Zhong, Min Ye & Fuling Yan. (2023) A review of studies on gut microbiota and levodopa metabolism. Frontiers in Neurology 14.
Crossref
Crossref
D. Woitalla, C. Buhmann, R. Hilker-Roggendorf, G. Höglinger, J. Koschel, T. Müller & D. Weise. (2023) Role of dopamine agonists in Parkinson's disease therapy. Journal of Neural Transmission 130:6, pages 863-873.
Crossref
Crossref
Linda Molteni, Bruno Charlier, Viviana Izzo, Albino Coglianese, Valeria Conti, Roberto Eleopra, Roberto Cilia, Chiara Capelli, Annachiara D’Urso & Ugo de Grazia. (2023) Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples. Molecules 28:11, pages 4264.
Crossref
Crossref
Valentina Leta, Lisa Klingelhoefer, Katherine Longardner, Marta Campagnolo, Hafize Çotur Levent, Federico Aureli, Vinod Metta, Roongroj Bhidayasiri, Guy Chung‐Faye, Cristian Falup‐Pecurariu, Fabrizio Stocchi, Peter Jenner, Tobias Warnecke & K. Ray Chaudhuri. (2023) Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease. European Journal of Neurology 30:5, pages 1465-1480.
Crossref
Crossref
Masahiro NAGAI, Satoshi TADA, Yuki YAMANISHI, Noriyuki MIYAUE & Rina ANDO. (2023) Differing Patterns of Diurnal Variation and Impact of Antacids on Levodopa Pharmacokinetics in Patients with Parkinson's Disease. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 54:1, pages 3-8.
Crossref
Crossref
Jocelyn J. Chang, Sanjay R.V. Gadi, Aleksandar Videnovic, Braden Kuo & Trisha S. Pasricha. (2023) Impact of outpatient gastroenterology consult on pharmacotherapy and management of gastrointestinal symptoms in Parkinson’s Disease. Clinical Parkinsonism & Related Disorders 9, pages 100215.
Crossref
Crossref
Erik Wollmer & Sandra Klein. (2022) Patient-specific in vitro drug release testing coupled with in silico PBPK modeling to forecast the in vivo performance of oral extended-release levodopa formulations in Parkinson’s disease patients. European Journal of Pharmaceutics and Biopharmaceutics 180, pages 101-118.
Crossref
Crossref
Roongroj Bhidayasiri, Warongporn Phuenpathom, Ai Huey Tan, Valentina Leta, Saisamorn Phumphid, K. Ray Chaudhuri & Pramod Kumar Pal. (2022) Management of dysphagia and gastroparesis in Parkinson’s disease in real-world clinical practice – Balancing pharmacological and non-pharmacological approaches. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Hellen Windolf, Rebecca Chamberlain, Jörg Breitkreutz & Julian Quodbach. (2022) 3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy. Pharmaceutics 14:5, pages 931.
Crossref
Crossref
Glenardi Glenardi, Tutwuri HandayaniJimmy BarusGhea Mangkuliguna. (2022) Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease. Neurology Clinical Practice 12:2, pages 139-148.
Crossref
Crossref
Joji Fujikawa, Ryoma Morigaki, Nobuaki Yamamoto, Teruo Oda, Hiroshi Nakanishi, Yuishin Izumi & Yasushi Takagi. (2022) Therapeutic Devices for Motor Symptoms in Parkinson’s Disease: Current Progress and a Systematic Review of Recent Randomized Controlled Trials. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Arshad Mahmood, Alia Erum, Sophia Mumtaz, Ume Ruqia Tulain, Nadia Shamshad Malik & Mohammed S. Alqahtani. (2022) Preliminary Investigation of Linum usitatissimum Mucilage-Based Hydrogel as Possible Substitute to Synthetic Polymer-Based Hydrogels for Sustained Release Oral Drug Delivery. Gels 8:3, pages 170.
Crossref
Crossref
Delaram Safarpour, Kaveh Sharzehi & Ronald F. Pfeiffer. (2022) Gastrointestinal Dysfunction in Parkinson’s Disease. Drugs 82:2, pages 169-197.
Crossref
Crossref
Dag Nyholm & Wolfgang H. Jost. (2022) Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance. Therapeutic Advances in Neurological Disorders 15, pages 175628642211080.
Crossref
Crossref
Iryna Karaban, Nina Karasevych & Tetyana Hasiuk. (2021) Prospects of successful treatment of Parkinson's disease
using apomorphine. Ageing & Longevity:4 2021, pages 1-26.
Crossref
Crossref
Moslem Mansour Lakouraj, Masoume Rezaei & Vahid Hasantabar. (2021) Synthesis, characterization and in-vitro prolonged release of L-DOPA using a novel amphiphilic hydrogel based on sodium alginate-polypyrrole. International Journal of Biological Macromolecules 193, pages 609-618.
Crossref
Crossref
I.M. Karaban, N.V. Karasevych & T.V. Hasiuk. (2021) Prospects for successful treatment of Parkinson’s disease with the use of apomorphine. INTERNATIONAL NEUROLOGICAL JOURNAL 17:4, pages 54-73.
Crossref
Crossref
Manon Auffret, Vincent Meuric, Emile Boyer, Martine Bonnaure-Mallet & Marc Vérin. (2021) Oral Health Disorders in Parkinson’s Disease: More than Meets the Eye. Journal of Parkinson's Disease 11:4, pages 1507-1535.
Crossref
Crossref
Angelo Antonini, Per Odin, Rajesh Pahwa, Jason Aldred, Ali Alobaidi, Yash J. Jalundhwala, Pavnit Kukreja, Lars Bergmann, Sushmitha Inguva, Yanjun Bao & K. Ray Chaudhuri. (2021) The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review. Advances in Therapy 38:6, pages 2854-2890.
Crossref
Crossref
Bart Hens, Patrick Augustijns, Hans Lennernäs, Mark McAllister & Bertil Abrahamsson. (2021) Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare. Frontiers in Medicine 8.
Crossref
Crossref
Kathryn A. Chung & Ronald F. Pfeiffer. (2020) Gastrointestinal dysfunction in the synucleinopathies. Clinical Autonomic Research 31:1, pages 77-99.
Crossref
Crossref
Emma McAlister, Bridie Dutton, Lalitkumar K. Vora, Li Zhao, Anastasia Ripolin, Dk Siti Zawanah Binti Pg Hj Zahari, Helen L. Quinn, Ismaiel A. Tekko, Aaron J. Courtenay, Stephen A. Kelly, Aoife M. Rodgers, Lilach Steiner, Galit Levin, Etgar Levy‐Nissenbaum, Nava Shterman, Helen O. McCarthy & Ryan F. Donnelly. (2020) Directly Compressed Tablets: A Novel Drug‐Containing Reservoir Combined with Hydrogel‐Forming Microneedle Arrays for Transdermal Drug Delivery. Advanced Healthcare Materials 10:3.
Crossref
Crossref
Li-Fei Zheng, Sumei Liu, Li Zhou, Xiao-Li Zhang, Xiao Yu & Jin-Xia Zhu. 2021. Dopamine in the Gut. Dopamine in the Gut
133
202
.
R. Alberto Travagli, Kirsteen N. Browning & Michael Camilleri. (2020) Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. Nature Reviews Gastroenterology & Hepatology 17:11, pages 673-685.
Crossref
Crossref
M. Senek, D. Nyholm & E. I. Nielsen. (2020) Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism. Scientific Reports 10:1.
Crossref
Crossref
Hakan Runvik, Alexander Medvedev & Maria C. Kjellsson. (2020)
Impulsive Feedback Modeling of Levodopa Pharmacokinetics Subject to Intermittently Interrupted Gastric Emptying
*
.
Impulsive Feedback Modeling of Levodopa Pharmacokinetics Subject to Intermittently Interrupted Gastric Emptying
*
.
Ronald F. Pfeiffer, Stuart H. Isaacson & Rajesh Pahwa. (2020) Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. Parkinsonism & Related Disorders 76, pages 63-71.
Crossref
Crossref
Jade Kenna & Ryan S. Anderton. 2020. Genetics, Neurology, Behavior, and Diet in Parkinson's Disease. Genetics, Neurology, Behavior, and Diet in Parkinson's Disease
569
582
.
Peter A. LeWitt, Nir Giladi & Nadav Navon. (2019) Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease. Parkinsonism & Related Disorders 65, pages 131-138.
Crossref
Crossref
Cheol Min Shin, Yoon Jin Lee, Jong-Min Kim, Jee Young Lee, Kyung-Joon Kim, Yoon Jin Choi, Nayoung Kim & Dong Ho Lee. (2018) DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial. Parkinsonism & Related Disorders 54, pages 84-89.
Crossref
Crossref
Hana You, Louise-Laure Mariani, Graziella Mangone, Delphine Le Febvre de Nailly, Fanny Charbonnier-Beaupel & Jean-Christophe Corvol. (2018) Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease. Cell and Tissue Research 373:1, pages 111-135.
Crossref
Crossref
Julia Staisch, Gene Bakis & John Nutt. (2018) A wrinkle in ON-time - A GI structural abnormality confounding levodopa therapy with Duodopa rescue; a case study. Parkinsonism & Related Disorders 50, pages 130-131.
Crossref
Crossref
Ka Lun Lai, Yuan Fang, Hao Han, Qingqing Li, Shuai Zhang, Ho Yin Li, Shing Fung Chow, Tai Ning Lam & Wai Yip Thomas Lee. (2018) Orally-dissolving film for sublingual and buccal delivery of ropinirole. Colloids and Surfaces B: Biointerfaces 163, pages 9-18.
Crossref
Crossref
Erik Wollmer & Sandra Klein. (2017) A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson’s disease. International Journal of Pharmaceutics 533:1, pages 298-314.
Crossref
Crossref
Aravind Mittur, Suneel Gupta & Nishit B. Modi. (2017) Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa. Clinical Pharmacokinetics 56:9, pages 999-1014.
Crossref
Crossref
Andrew Su, Rita Gandhy, Carrolee Barlow & George Triadafilopoulos. (2017) A practical review of gastrointestinal manifestations in Parkinson's disease. Parkinsonism & Related Disorders 39, pages 17-26.
Crossref
Crossref
Harith Akram, Chengyuan Wu, Jonathan Hyam, Thomas Foltynie, Patricia Limousin, Enrico De Vita, Tarek Yousry, Marjan Jahanshahi, Marwan Hariz, Timothy Behrens, John Ashburner & Ludvic Zrinzo. (2017)
l
-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease
. Movement Disorders 32:6, pages 874-883.
Crossref
Crossref
Johan Virhammar & Dag Nyholm. (2016) Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience. Therapeutic Advances in Neurological Disorders 10:3, pages 171-187.
Crossref
Crossref
Louise Curley, Jordan Hinton, Cameron Marjoribanks, Ali Mirjalili, Julia Kennedy & Darren Svirskis. (2017) Magnetic Resonance Imaging to Visualize Disintegration of Oral Formulations. Journal of Pharmaceutical Sciences 106:3, pages 745-750.
Crossref
Crossref
R. Sane & M. Sinz. 2017. Drug Metabolism in Diseases. Drug Metabolism in Diseases
1
19
.
Stuart Isaacson, Mark Lew, William Ondo, Jean Hubble, Thomas Clinch & Fernando Pagan. (2016) Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease. Movement Disorders Clinical Practice 4:1, pages 78-83.
Crossref
Crossref
Michael M. LippRichard BatyckyJerome MooreMika LeinonenMartin I. Freed. (2016) Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Science Translational Medicine 8:360.
Crossref
Crossref
Dee E. SilverRichard M. Trosch. (2016) Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease. Neurology 86:14_supplement_1.
Crossref
Crossref
Yasaman Kianirad & Tanya Simuni. (2016) Novel Approaches to Optimization of Levodopa Therapy for Parkinson’s Disease. Current Neurology and Neuroscience Reports 16:4.
Crossref
Crossref
Paul A. Nausieda, Ann Hsu, Lawrence Elmer, Ramon A. Gil, Joerg Spiegel, Carlos Singer, Sarita Khanna, Robert Rubens, Sherron Kell, Nishit B. Modi & Suneel Gupta. (2015) Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials. Journal of Parkinson's Disease 5:4, pages 837-845.
Crossref
Crossref
L. Epprecht, S. R. Schreglmann, O. Goetze, D. Woitalla, C. R. Baumann & D. Waldvogel. (2015) Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal. Journal of Neurology 262:8, pages 1946-1953.
Crossref
Crossref
M. Luinstra, A. W. F. Rutgers, H. Dijkstra, F. Grasmeijer, P. Hagedoorn, J. M. J. Vogelzang, H. W. Frijlink & A. H. de Boer. (2015) Can Patients with Parkinson’s Disease Use Dry Powder Inhalers during Off Periods?. PLOS ONE 10:7, pages e0132714.
Crossref
Crossref
Oluwadamilola O Ojo & Hubert H Fernandez. (2015) Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease. Future Neurology 10:3, pages 191-201.
Crossref
Crossref
Eamonn M.M. Quigley. (2015) Other Forms of Gastroparesis. Gastroenterology Clinics of North America 44:1, pages 69-81.
Crossref
Crossref
Kousuke Baba & Hideki Mochizuki. (2015) VIII. Future Treatment of Parkinson's Disease. Nihon Naika Gakkai Zasshi 104:8, pages 1591-1596.
Crossref
Crossref
Simone M. R. Camargo, Raphael N. Vuille-dit-Bille, Luca Mariotta, Tamara Ramadan, Katja Huggel, Dustin Singer, Oliver Götze & François Verrey. (2014) The Molecular Mechanism of Intestinal Levodopa Absorption and Its Possible Implications for the Treatment of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics 351:1, pages 114-123.
Crossref
Crossref
Marina Senek & Dag Nyholm. (2013) Continuous Drug Delivery in Parkinson’s Disease. CNS Drugs 28:1, pages 19-27.
Crossref
Crossref
Sarah Marrinan, Anton V. Emmanuel & David J. Burn. (2014) Delayed gastric emptying in Parkinson's disease. Movement Disorders 29:1, pages 23-32.
Crossref
Crossref
Karl-Erik Rahne, Carl Tagesson & Dag Nyholm. (2013) Motor fluctuations and Helicobacter pylori in Parkinson’s disease. Journal of Neurology 260:12, pages 2974-2980.
Crossref
Crossref
Dag Nyholm, Per Odin, Anders Johansson, Krai Chatamra, Charles Locke, Sandeep Dutta & Ahmed A. Othman. (2012) Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients. The AAPS Journal 15:2, pages 316-323.
Crossref
Crossref
Sheena K Aurora, Spyridon Papapetropoulos, Shashidhar H Kori, Archana Kedar & Thomas L Abell. (2013) Gastric stasis in migraineurs: Etiology, characteristics, and clinical and therapeutic implications. Cephalalgia 33:6, pages 408-415.
Crossref
Crossref
D. Nyholm, M. Ehrnebo, T. Lewander, C. G. Trolin, T. Bäckström, G. Panagiotidis, J. Spira, C. Nyström & S.-M. Aquilonius. (2013) Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurologica Scandinavica 127:2, pages 124-132.
Crossref
Crossref
C. Moreau, A. Annic, D. Devos & L. Defebvre. (2013) Comment gérer un traitement par Duodopa® dans la maladie de Parkinson évoluée ?. Pratique Neurologique - FMC 4:1, pages 22-27.
Crossref
Crossref
Dag Nyholm. (2012) Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety. Parkinsonism & Related Disorders 18:8, pages 916-929.
Crossref
Crossref
Cuiping Chen, Verne E. Cowles, Mike Sweeney, Igor D. Stolyarov & Sergey N. Illarioshkin. (2013) Pharmacokinetics of Levodopa/Carbidopa Delivered From Gastric‐Retentive Extended‐Release Formulations in Patients With Parkinson's Disease. The Journal of Clinical Pharmacology 52:7, pages 1069-1077.
Crossref
Crossref
L. Wang, N. P. Murphy, A. Stengel, M. Goebel-Stengel, D. H. St Pierre, N. T. Maidment & Y. Taché. (2012) Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats. Neurogastroenterology & Motility 24:5, pages e235-e245.
Crossref
Crossref
Dag Nyholm, Tommy Lewander, Cecilia Gomes-Trolin, Tobias Bäckström, Georgios Panagiotidis, Mats Ehrnebo, Christer Nyström & Sten-Magnus Aquilonius. (2012) Pharmacokinetics of Levodopa/Carbidopa Microtablets Versus Levodopa/Benserazide and Levodopa/Carbidopa in Healthy Volunteers. Clinical Neuropharmacology 35:3, pages 111-117.
Crossref
Crossref
Cuiping Chen, Verne E. Cowles, Michael Sweeney, Igor D. Stolyarov & Sergey N. Illarioshkin. (2012) Pharmacokinetics and Pharmacodynamics of Gastroretentive Delivery of Levodopa/Carbidopa in Patients With Parkinson Disease. Clinical Neuropharmacology 35:2, pages 67-72.
Crossref
Crossref
Dag Nyholm, Anders Johansson, Sten-Magnus Aquilonius, Elisabeth Hellquist, Hans Lennernäs & Håkan Askmark. (2012) Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease. Clinical Neuropharmacology 35:1, pages 6-14.
Crossref
Crossref
Eamonn M.M. Quigley, Seamus O'Mahony & Zaid Heetun. (2011) Motility Disorders in the Patient with Neurologic Disease. Gastroenterology Clinics of North America 40:4, pages 741-764.
Crossref
Crossref
Gareth J. Sanger, John Broad & David H. Alpers. 2011. Peptide Drug Discovery and Development. Peptide Drug Discovery and Development
269
294
.
Ronald F. Pfeiffer. 2011. Parkinson's Disease. Parkinson's Disease
257
273
.
D. Salat-Foix, C. N. Andrews, J. Meddings & O. Suchowersky. (2014) Gastrointestinal Symptoms in Parkinson Disease: Clinical Aspects and Management. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 38:4, pages 557-564.
Crossref
Crossref
Ronald F. Pfeiffer. (2011) Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism & Related Disorders 17:1, pages 10-15.
Crossref
Crossref
Masahiro Nagai, Madoka Kubo, Noriko Nishikawa & Masahiro Nomoto. (2010) Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations. Parkinsonism & Related Disorders 16:10, pages 697-699.
Crossref
Crossref
Dag Nyholm, Hans Lennernäs, Anders Johansson, Matias Estrada & Sten-Magnus Aquilonius. (2010) Circadian Rhythmicity in Levodopa Pharmacokinetics in Patients With Parkinson Disease. Clinical Neuropharmacology 33:4, pages 181-185.
Crossref
Crossref
Fabrizio Stocchi & Stefano Marconi. (2010) Factors Associated With Motor Fluctuations and Dyskinesia in Parkinson Disease. Clinical Neuropharmacology 33:4, pages 198-203.
Crossref
Crossref
Angelo Antonini, K. Ray Chaudhuri, Pablo Martinez-Martin & Per Odin. (2010) Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs Disease. CNS Drugs 24:2, pages 119-129.
Crossref
Crossref
Deborah J. Culley, Meredith R. Brooks & Gregory Crosby. 2010. Cottrell and Young's Neuroanesthesia. Cottrell and Young's Neuroanesthesia
390
399
.
Peter Jenner, Michael Könen-Bergmann, Cornelia Schepers & Sebastian Haertter. (2009) Pharmacokinetics of a Once-Daily extended-release formulation of pramipexole in healthy male volunteers: Three studies. Clinical Therapeutics 31:11, pages 2698-2711.
Crossref
Crossref